JAK2 and lung cancer: Another investigation (30) highlighted the relationship between JAK2/JAK3 mutations in lung cancer and the expression of programmed cell death ligand-1 (PD-L1), implying potential benefits of immunotherapy for patients harboring JAK3 gene mutations.